Vaccinex says neoadjuvant melanoma pilot study links pepinemab regimens to immune remodeling, longer recurrence-free survivalPUBT·Oct 7, 2026 at 12:32 PMVCNX0.00%
Vaccinex Reports 2025 Annual Financial Results | VCNX Stock NewsStockTitan·Apr 29, 2026 at 04:05 PMVCNX0.00%IBBQ-0.39%
KDventures' portfolio company SVF Vaccines names Raheleh Nassaji as CEO to drive SVF-001 vaccine to phase 1 trials.Unusual Whales·Feb 10, 2026 at 01:02 PMIBBQ-0.39%SBIO-0.49%
Vaccinex will present positive clinical results of neoadjuvant treatment with pepinemab at ASCO Annual Meeting. Enhanced immunotherapy in head and neck cancer patients.Unusual Whales·May 27, 2025 at 01:07 PMVCNX0.00%
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual MeetingGlobeNewswire·May 27, 2025 at 12:45 PMVCNX0.00%
Vaccinex will present data at AACR showing pepinemab's unique mechanism in enhancing immunotherapy, correlating with clinical benefit in HNSCC and melanoma studies.Unusual Whales·Apr 21, 2025 at 01:07 PMVCNX0.00%
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) | VCNX Stock NewsStockTitan·Apr 21, 2025 at 12:45 PMVCNX0.00%
Vaccinex to delist Common Stock from Nasdaq due to decision; stock suspended since Dec 18, 2024.Unusual Whales·Mar 19, 2025 at 04:27 AMVCNX0.00%
Vaccinex to delist its common stock from Nasdaq after trading suspended since Dec 18, 2024.Unusual Whales·Mar 17, 2025 at 04:07 AMVCNX0.00%
Vaccinex plans to delist its Common Stock from Nasdaq after suspension since Dec 2024. Company uses SEMA4D blockage to treat neurodegenerative diseases.Unusual Whales·Mar 14, 2025 at 12:47 AMVCNX0.00%
Vaccinex to delist its common stock (OTC: VCNX) from Nasdaq due to trading suspension since Dec 18, 2024.Unusual Whales·Mar 11, 2025 at 11:37 PMVCNX0.00%
Vaccinex plans Nasdaq exit as Alzheimer market pressure growsPharmaceutical Technology·Mar 10, 2025 at 08:15 PMVCNX0.00%
Vaccinex to delist Common Stock from Nasdaq; suspended since Dec 18, 2024; aiming a differentiated approach in treating neurodegenerative diseases.Unusual Whales·Mar 7, 2025 at 10:32 PMVCNX0.00%
